Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Therakos Development Limited currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner, Joanne Hama, who is the busiest examiner for the portfolio with 1 pending action. The workload is confined to 1 distinct art unit, representing a very focused prosecution presence at the USPTO.
The presence of Joanne Hama as the only examiner indicates that the company's current patent activity is concentrated. Practitioners should note that with only 1 pending office action, there is no internal data to compare examiner performance or art unit trends within this portfolio. This focus means that the outcome of this specific matter will define the company's current success rate in the Biotechnology & Pharmaceuticals sector. The ratio of pending office actions to distinct examiners stands at 1 to 1. Because the workload is limited to 1 distinct art unit, the company's strategy is tied to the specific examination practices of that unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAMA, JOANNE | 1 | 25.7% | +40.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19383352 | METHOD FOR GENERATING IMMUNOREGULATORY CELLS IN A BLOOD-DERIVED SAMPLE | HAMA, JOANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19383352 | METHOD FOR GENERATING IMMUNOREGULATORY CELLS IN A BLOOD-DERIVED SAMPLE | HAMA, JOANNE | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19383352 | METHOD FOR GENERATING IMMUNOREGULATORY CELLS IN A BLOOD-DERIVED SAMPLE | HAMA, JOANNE | 1647 | §103DP | Non-Final OA | — | Pending | Nov 07, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial